Viveve (NSDQ:VIVE) today announced results from a sub-analysis of its Viveve 1 trial exploring the use of the Viveve system for treating vaginal introitus in women with sexual dysfunction, touting improvements on the Female Sexual Functions Index. The Englewood, Colo.-based company’s Viveve System is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus. Sub-analysis results […]
Viveve
Viveve prices $30m offering
Viveve (NSDQ:VIVE) late last week priced an upcoming offering, looking to raise $30 million to support its Viveve system. The Sunnyvale, Calif.-based company’s Viveve System is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus. Viveve said it plans to offer approximately 7.5 million shares of stock at $4 per share, with a 30-day underwriter’s […]
Viveve Medical reports success treating vaginal laxity
Viveve Medical recently published the results of a clinical study of its Viveve I treatment in the Journal of Sexual Medicine, showing that women who received the treatment reported being more likely to have no vaginal laxity. The Viveve Treatment of the Vaginal Introitus to Evaluate Efficacy study is one of the first studies to study […]
Viveve moves headquarters to Colorado
Viveve (NSDQ:VIVE) said today it is relocating its corporate headquarters to Englewood, Colo. from Sunnyvale, Calif. The company said it signed a lease agreement for a new facility in Englewood, with physical relocation planned for the end of the 1st quarter of 2017, pending the build-out of the office and warehouse facilities. “Last year was a […]
Viveve wins FDA 510(k) for its Viveve System
Viveve (NSDQ:VIVE) said today it won FDA 510(k) clearance for its Viveve System, now cleared for use in general surgical procedures for electrocoagulation and hemostasis. The company’s Viveve System is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus. “FDA 510(k) clearance for the Viveve System represents a major milestone in our efforts to […]
Viveve hits the market Down Under
Viveve (NSDQ:VIVE) said today it it won regulatory clearance from Australia’s Therapeutic Goods Administration for its Viveve non-surgical treatment for post-partum laxity of the vaginal introitus. The Sunnyvale, Calif.-based company said it inked a distribution partnership deal in Australia and New Zealand with medical product supplier Device Consulting, which will support the regional distribution of the Viveve […]
Viveve lands S. Korea regulatory clearance for Viveve System
Viveve (NSDQ:VIVE) said today it won regulatory approval from the Ministry of Food and Drug Safety in South Korea for its Viveve non-surgical treatment for post-partum laxity of the vaginal introitus. The company said it already inked an exclusive distribution partnership in South Korea with JOYMG, a medical device distributor in the region. “The receipt of market approval […]
Viveve inks Latin American distribution deals
Viveve (NSDQ:VIVE) said today it inked 6 new distribution deals to expand the availability of its Viveve non-surgical treatment for post-partum laxity of the vaginal introitus to 14 Latin American countries. The women’s health company said it inked deals with Sirex S.A., Torregal, Alphaeon Columbia S.A.S., Vitre-Tech, Coolmed S.A., Adenor S.A. and MARC Group International to bring […]
Viveve closes $16m uplisting
Viveve (NSDQ:VIVE) said today that its uplisting to the NASDAQ exchange grossed $15.5 million, including an unwriters over-allotment. Sunnyvale, Calif.-based Viveve, which makes a non-surgical treatment for post-partum laxity of the vaginal introitus, said it sold more than 3.1 million shares at $5 apiece, for net proceeds of about $14 million. Earlier this week Viveve tweaked the value […]
Viveve ups share count, lowers share price in $13.5m NASDAQ uplisting
Viveve (OTC:VIVMD) today tweaked the value of its uplisting from the over-the-counter exchange to the NASDAQ board, expecting to sell 2.7 million shares at $5 per share to bring in $13.5 million. Sunnyvale, Calif.-based Viveve makes a non-surgical treatment for post-partum laxity of the vaginal introitus. The company put a 1-for-8 reverse split into place in April, and said […]
Viveve boosts terms for $13m NASDAQ uplisting
Updated to correct Scott Durbin’s title to CFO Viveve (OTC:VIVMD) said today that it’s boosting the value of a pending uplisting from the over-the-counter exchange to the NASDAQ board. Sunnyvale, Calif.-based Viveve makes a non-surgical treatment for post-partum laxity of the vaginal introitus. The company put a 1-for-8 reverse split into place last month; today Viveve said it […]